Filing Flows

Filing Flows › Vertex Pharmaceuticals (VRTX) › Next earnings date

Vertex Pharmaceuticals (VRTX) earnings: missed the estimate

Vertex Pharmaceuticals (VRTX) reported on Nov 2, 2026 and missed the EPS estimate: $4.76 against $4.78 (-0.5%). Revenue was $3.4B for Q3 2026, +12% year over year. The stock moved -5.0% on the report. It beat the EPS estimate in 60% of the quarters on record.

Last result−0.5% vs estimate
Beat rate60%

The last report

Vertex Pharmaceuticals reported revenue of $3.4B for the third quarter 2026 (+12% Y/Y), net earnings $654M: Total CF product revenues, net $3.3B, CASGEVY $99.2M, JOURNAVX $58.3M. How it makes money → · Every quarter →

Vertex Pharmaceuticals: EPS against the estimate, last 5 reportsVertex Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported$4.58$4.80Nov 25$4.58$4.65Feb 26$4.31$4.47May 26$4.75$4.73Aug 26$4.78$4.76Nov 26
Latest (Nov 26): Estimate $4.78, Reported $4.76.
VRTX: the stock's move on each reportVRTX: the stock's move on each reportNov 2, 2026-5.0%Aug 3, 2026+0.3%May 4, 2026+0.1%Feb 12, 2026+6.6%Nov 3, 2025-0.9%

Vertex Pharmaceuticals' latest quarter

Vertex Pharmaceuticals, Q3 2026: revenue $3.4B (+12% year over year), operating margin 20.7%, net earnings $654M, operating cash flow $643M. The chart follows the revenue to costs, profit and cash.

Questions

Did Vertex Pharmaceuticals beat earnings?

Vertex Pharmaceuticals (VRTX) reported on Nov 2, 2026 and missed the EPS estimate: $4.76 against $4.78 (-0.5%).

When does VRTX report earnings?

The next date is not set yet.

Does Vertex Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.